Compositions comprising decitabine and tetrahydrouridine and uses thereof
Joseph Desimone, Glen Ellyn, IL (US); and Yogen Saunthararajah, Cleveland, OH (US)
Assigned to BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US)
Filed by The Board of Trustees of the University of Illinois, Urbana, IL (US)
Filed on Jul. 14, 2021, as Appl. No. 17/375,585.
Application 17/375,585 is a continuation of application No. 16/685,956, filed on Nov. 15, 2019, granted, now 11,096,953.
Application 16/685,956 is a continuation of application No. 15/875,727, filed on Jan. 19, 2018, granted, now 10,517,884, issued on Dec. 31, 2019.
Application 15/875,727 is a continuation of application No. 15/044,805, filed on Feb. 16, 2016, granted, now 9,895,391, issued on Feb. 20, 2018.
Application 15/044,805 is a continuation of application No. 13/414,546, filed on Mar. 7, 2012, granted, now 9,265,785, issued on Feb. 23, 2016.
Application 13/414,546 is a continuation in part of application No. 13/141,669, granted, now 9,259,469, issued on Feb. 16, 2016, previously published as PCT/US2009/069035, filed on Dec. 21, 2009.
Claims priority of provisional application 61/486,428, filed on May 16, 2011.
Claims priority of provisional application 61/158,937, filed on Mar. 10, 2009.
Claims priority of provisional application 61/139,710, filed on Dec. 22, 2008.
Prior Publication US 2022/0023328 A1, Jan. 27, 2022
1. A composition for oral administration comprising about 10 to about 150 mg/m decitabine and about 100 to about 500 mg/m tetrahydrouridine and a pharmaceutically acceptable excipient, wherein the tetrahydrouridine is located on a surface of a capsule or tablet and the decitabine is located within the capsule or tablet.